Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. Cystic Fibrosis Inhaled Tobramycin Study Group.

No abstract is available for this paper.

• Publication year

  1999

• Venue

  New England Journal of Medicine

• Publication date

  1999-01-07

• Fields of study

  Medicine

• Identifiers
  DOI 10.1056/NEJM199901073400104PMID 9878641
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Cystic Fibrosis

  2009cited by this paper
• Microbiology of sputum from patients at cystic fibrosis centers in the United States.

  1998cited by this paper
• A comparison of peak sputum tobramycin concentration in patients with cystic fibrosis using jet and ultrasonic nebulizer systems. Aerosolized Tobramycin Study Group.

  1997cited by this paper
• Cystic fibrosis.

  1996cited by this paper
• Standardization of Spirometry, 1994 Update. American Thoracic Society.

  1995cited by this paper
• Effect of aerosolized recombinant human DNase on exacerbations of respiratory symptoms and on pulmonary function in patients with cystic fibrosis. The Pulmozyme Study Group.

  1994cited by this paper
• Generation of Aerosolized Drugs

  1994cited by this paper
• Outcome measures for clinical trials in cystic fibrosis. Summary of a Cystic Fibrosis Foundation consensus conference.

  1994cited by this paper
• Efficacy of aerosolized tobramycin in patients with cystic fibrosis.

  1993cited by this paper
• Treatment of pulmonary disease in patients with cystic fibrosis

  1993cited by this paper
• Elevated exoenzyme expression by Pseudomonas aeruginosa is correlated with exacerbations of lung disease in cystic fibrosis.

  1993cited by this paper
• The changing epidemiology of cystic fibrosis.

  1993cited by this paper
• Prediction of mortality in patients with cystic fibrosis.

  1992cited by this paper
• Microbiology of airway disease in patients with cystic fibrosis

  1991cited by this paper
• Long‐term tobramycin aerosol therapy in cystic fibrosis

  1989cited by this paper
• Long‐term effects of inhaled tobramycin in patients with cystic fibrosis colonized with Pseudomonas aeruginosa

  1989cited by this paper
• Review of sulfite sensitivity.

  1985cited by this paper
• Changes in the normal maximal expiratory flow-volume curve with growth and aging.

  1983cited by this paper
• Inhaled antibiotics in cystic fibrosis.

  1983cited by this paper
• Aerosol carbenicillin and gentamicin treatment of Pseudomonas aeruginosa infection in patients with cystic fibrosis.

  1981cited by this paper
• Multiple of isolates of Pseudomonas aeruginosa with differing antimicrobial susceptibility patterns from patients with cystic fibrosis.

  1979cited by this paper
• Rhode Island Hospital

  1883cited by this paper

• Analysis of the structure and surfactant activity of formulations with exogenous pulmonary surfactant as an antibiotic carrier.

  2025cites this paper
• State-of-the-Art Review: Transformative Changes in the Care of People With Cystic Fibrosis: Implications for Infectious Diseases Specialists.

  2025cites this paper
• Thirty‐Year Prevalence of Spontaneous Hemoptysis in Palliated Single Ventricle Circulation

  2025cites this paper
• Synergistic action between peptide-neomycin conjugates and polymyxin B against multidrug-resistant gram-negative pathogens

  2025cites this paper
• Tolerability and Pharmacokinetic Evaluation of Inhaled Dry Powder Tobramycin in Children with Cystic Fibrosis

  2025cites this paper
• Comparative efficacy and safety of inhaled antibiotics in managing chronic Pseudomonas aeruginosa infection in patients with cystic fibrosis and bronchiectasis: a systematic review and network meta-analysis

  2025cites this paper
• Prevention of chronic pneumonia in children with severe motor and intellectual disabilities by long-term tobramycin inhalation: Its benefits and limitations.

  2025cites this paper
• Airway Colonization in Children with Medical Complexity: Challenges and Management Strategies

  2025cites this paper
• Inhaled antibiotics for treatment and prevention of ventilator-associated pneumonia. Narrative review

  2025cites this paper
• New anti-infective approaches to treat airway infections in persons with cystic fibrosis and bronchiectasis.

  2025cites this paper
• Molecular endotyping in people with bronchiectasis based on response to antibiotic treatment: iBEST study

  2025cites this paper
• An update on targeting airway inflammation in cystic fibrosis

  2025cites this paper
• Association between inhaled antibiotic use and treatment-emergent organisms among Canadian people with cystic fibrosis.

  2025cites this paper
• Process and validity of linking cystic fibrosis patient registry with national Medicaid databases.

  2024cites this paper
• Therapeutic Interventions for Pseudomonas Infections in Cystic Fibrosis Patients: A Review of Phase IV Trials

  2024cites this paper
• Inhaled colistimethate sodium in patients with bronchiectasis and Pseudomonas aeruginosa infection: results of PROMIS-I and PROMIS-II, two randomised, double-blind, placebo-controlled phase 3 trials assessing safety and efficacy over 12 months.

  2024cites this paper
• The Association between Aminoglycoside Exposure and Ototoxicity in Children with Cystic Fibrosis

  2024cites this paper
• Monitoring cystic fibrosis airway infections with Pseudomonas aeruginosa with anti-OprF serum antibodies.

  2024cites this paper
• Decoding genetic susceptibility to Pseudomonas aeruginosa infections in cystic fibrosis

  2024cites this paper
• Daily variability of Pseudomonas aeruginosa density in cystic fibrosis sputum.

  2024cites this paper
• Definitions of pulmonary exacerbation in people with cystic fibrosis: a scoping review

  2024cites this paper
• P. aeruginosa tRNA-fMet halves secreted in outer membrane vesicles suppress lung inflammation in cystic fibrosis

  2024cites this paper
• Antibiotic loaded inhalable liposomal nanoparticles against lower respiratory tract infections: Challenges, recent advances, and future perspectives

  2024cites this paper
• Phage Therapy for Respiratory Infections: Opportunities and Challenges

  2024cites this paper
• Antibiotic treatment of bacterial lung infections in cystic fibrosis

  2024cites this paper
• Geschichtlicher Abriss der Mukoviszidose

  2024cites this paper
• Intravenous Tobramycin Inhalation for Patients With Advanced Bronchiectasis With Pseudomonas aeruginosa Infection in Home Medical Care: A Report of Two Cases

  2024cites this paper
• Chronic inhaled antibiotic therapy in people with cystic fibrosis with Pseudomonas aeruginosa infection in Germany.

  2023cites this paper
• Lessons from the history of inorganic nanoparticles for inhalable diagnostics and therapeutics.

  2023cites this paper
• Disparities and therapeutic advances in cystic fibrosis

  2023cites this paper
• Advancing the pipeline of cystic fibrosis clinical trials: a new roadmap with a global trial network perspective.

  2023cites this paper
• Chronic daily respiratory care needs in people with cystic fibrosis treated with highly effective cystic fibrosis transmembrane conductance regulator modulators

  2023cites this paper
• Treatment with inhaled antibiotics in bronchiectasis, side effects, and evaluation of the tolerance test; analysis from the BATTLE randomized controlled trial

  2023cites this paper
• Breath of fresh insight: unraveling the evolution of our understanding of cystic fibrosis pulmonary exacerbations

  2023cites this paper
• Ceftolozane/tazobactam plus tobramycin against free-floating and biofilm bacteria of hypermutable Pseudomonas aeruginosa epidemic strains: resistance mechanisms and synergistic activity: Running title: Ceftolozane/tazobactam plus tobramycin against Pseudomonas biofilm.

  2023cites this paper
• Preclinical Investigation of a Lipoglycopeptide Dry Powder Inhalation Therapy for the Treatment of Pulmonary MRSA Infection

  2023cites this paper
• A birth cohort approach to understanding cystic fibrosis lung infections.

  2023cites this paper
• Lessons from other fields of medicine, Part 2: Cystic fibrosis.

  2023cites this paper
• Management of respiratory tract exacerbations in people with cystic fibrosis: Focus on imaging

  2023cites this paper
• Association of the three-minute step test with the occurrence of pulmonary exacerbations in children with cystic fibrosis: a cross-sectional study.

  2023cites this paper
• Use of elexacaftor+tezacaftor+ivacaftor in individuals with cystic fibrosis and at least one F508del allele: a systematic review and meta-analysis

  2023cites this paper
• Brazilian guidelines for the pharmacological treatment of the pulmonary symptoms of cystic fibrosis. Official document of the Sociedade Brasileira de Pneumologia e Tisiologia (SBPT, Brazilian Thoracic Association)

  2023cites this paper
• Re-examining baseline lung function recovery following IV-treated pulmonary exacerbations.

  2023cites this paper
• Saline at lower tonicity in cystic fibrosis (SALTI-CF) trial comparing 0.9% versus 3% versus 6% nebulised saline

  2023cites this paper
• Current and Emerging Inhaled Antibiotics for Chronic Pulmonary Pseudomonas aeruginosa and Staphylococcus aureus Infections in Cystic Fibrosis

  2023cites this paper
• Stability Considerations for Bacteriophages in Liquid Formulations Designed for Nebulization

  2023cites this paper
• Role of inhaled antibiotics in the era of highly effective CFTR modulators

  2023cites this paper
• Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis.

  2023cites this paper
• Limited effects of azithromycin on the oropharyngeal microbiome in children with CF and early pseudomonas infection

  2023cites this paper
• Pharmacologic improvement of CFTR function rapidly decreases sputum pathogen density, but lung infections generally persist

  2023cites this paper
• Diagnosis and Management of Cystic Fibrosis Exacerbations

  2023cites this paper
• Community composition shapes microbial-specific phenotypes in a cystic fibrosis polymicrobial model system

  2022cites this paper
• Trends in Growth and Maturation in Children with Cystic Fibrosis Throughout Nine Decades

  2022cites this paper
• Indian Guidelines on Nebulization Therapy.

  2022cites this paper
• Newborn screening for cystic fibrosis: evaluation of benefits and Newborn screening for cystic fibrosis: evaluation of benefits and risks and recommendations for state newborn screening risks and recommendations for state newborn screening programs programs

  2022cites this paper
• Application of gap time analysis with flexible hazards to pulmonary exacerbations in the EPIC observational study

  2022cites this paper
• Blood mRNA biomarkers distinguish variable systemic and sputum inflammation at treatment initiation of inhaled antibiotics in cystic fibrosis: A prospective non-randomized trial

  2022cites this paper
• Antimicrobial therapies for prevention of recurrent acute exacerbations of COPD (AECOPD): beyond the guidelines

  2022cites this paper
• Medical interventions for chronic rhinosinusitis in cystic fibrosis.

  2022cites this paper
• Gram-negative bacteria act as a reservoir for aminoglycoside antibiotics that interact with host factors to enhance bacterial killing in a mouse model of pneumonia

  2022influential citation
• Diagnosis, management, and outcomes of pediatric tracheostomy‐associated infections: A scoping review

  2022cites this paper
• Synergistic Activity of Repurposed Peptide Drug Glatiramer Acetate with Tobramycin against Cystic Fibrosis Pseudomonas aeruginosa

  2022cites this paper
• A roadmap to pulmonary delivery strategies for the treatment of infectious lung diseases

  2022cites this paper
• Tobramycin safety and efficacy review article.

  2022cites this paper
• Inhaled antibiotics for pulmonary exacerbations in cystic fibrosis.

  2022cites this paper
• Bronchiectasis and inhaled tobramycin: A literature review.

  2022cites this paper
• The BATTLE study: Effects of long-term tobramycin inhalation solution (TIS) once daily on exacerbation rate in patients with non-cystic fibrosis bronchiectasis. Study protocol of a double blind, randomized, placebo-controlled trial: study protocol

  2022cites this paper
• Antimicrobial Strategies for Cystic Fibrosis

  2022cites this paper
• Inhaled anti-pseudomonal antibiotics for long-term therapy in cystic fibrosis.

  2022cites this paper
• Beyond borders: cystic fibrosis survival between Australia, Canada, France and New Zealand

  2022cites this paper
• Cystic Fibrosis: Highly Effective Targeted Therapeutics and the Impact on Sex and Racial Disparities.

  2022cites this paper
• Small Colonies, Bigger Problems? New Evidence That Staphylococcus aureus Small Colony Variants Can Worsen Lung Inflammation in Cystic Fibrosis Rats

  2022cites this paper
• Antimicrobial Stewardship in Cystic Fibrosis.

  2022cites this paper
• Effects of long-term tobramycin inhalation solution (TIS) once daily on exacerbation rate in patients with non-cystic fibrosis bronchiectasis

  2022cites this paper
• The Elusive Role of Airway Infection in Cystic Fibrosis Exacerbation.

  2022cites this paper
• Prevalence, trends and outcomes of long-term inhaled antibiotic treatment in people with cystic fibrosis without chronic Pseudomonas aeruginosa infection - A European cystic fibrosis patient registry data analysis.

  2022cites this paper
• Drugs, Drugs, Drugs: Current Treatment Paradigms in Cystic Fibrosis Airway Infections.

  2022cites this paper
• The Efficacy of an N-Acetylcysteine–Antibiotic Combination Therapy on Achromobacter xylosoxidans in a Cystic Fibrosis Sputum/Lung Cell Model

  2022cites this paper
• The Sense and Nonsense of Antimicrobial Susceptibility Testing in Cystic Fibrosis.

  2022cites this paper
• Azithromycin and Tobramycin Therapy in Cystic Fibrosis Pulmonary Exacerbations: Less Is More?

  2021cites this paper
• Dietary Supplements and Nutraceuticals under Investigation for COVID-19 Prevention and Treatment

  2021cites this paper
• Evolution of Antibiotic Tolerance Shapes Resistance Development in Chronic Pseudomonas aeruginosa Infections

  2021cites this paper
• Disconcerting and Counterintuitive Findings from a Trial of Exercise in Cystic Fibrosis: Can Exercise Make Our Patients Worse?

  2021cites this paper
• Antibiotic therapy for chronic infection with Burkholderia cepacia complex in people with cystic fibrosis.

  2021cites this paper
• Testing the effects of combining azithromycin with inhaled tobramycin for P. aeruginosa in cystic fibrosis: a randomised, controlled clinical trial

  2021cites this paper
• Aerosolized antibiotics in the treatment of hospital-acquired pneumonia/ventilator-associated pneumonia

  2021cites this paper
• Inhaled Medications Employed in Critically Ill Patients

  2021cites this paper
• Retracing changes in cystic fibrosis understanding and management over the past twenty years.

  2021cites this paper
• Combining Ivacaftor and Intensive Antibiotics Achieves Limited Clearance of Cystic Fibrosis Infections

  2021cites this paper
• Therapeutic Approach of Chronic Pseudomonas Infection in Cystic Fibrosis—A Network Meta-Analysis

  2021cites this paper
• The cystic fibrosis lung microenvironment alters antibiotic activity: causes and effects

  2021cites this paper
• Early Lung Disease Exhibits Bacterial-Dependent and -Independent Abnormalities in Cystic Fibrosis Pigs.

  2021cites this paper
• Optimizing Spray-Dried Porous Particles for High Dose Delivery with a Portable Dry Powder Inhaler

  2021cites this paper
• What shall we learn from TEACH?

  2021cites this paper
• Is it Worth Adding Systemic Antibiotics to Inhalational Tobramycin Therapy to Treat Pseudomonas Infections in Cystic Fibrosis?

  2021cites this paper
• Does Cefiderocol Have a Potential Role in Cystic Fibrosis Pulmonary Exacerbation Management?

  2021cites this paper
• Dry Powder Inhalers in the Digitalization Era: Current Status and Future Perspectives

  2021cites this paper
• Cystic fibrosis

  2021cites this paper
• Application of aerosol therapy in respiratory diseases in children: A Saudi expert consensus

  2021cites this paper
• In Vitro Comparison of Different Nebulizers Delivering 7% Hypertonic Saline

  2021cites this paper